Cited by 3Mesenchymal stem cell researchImmune cells in cancerPI3K/AKT/mTOR signaling in cancer

Mesenchymal stromal cells regulate THP-1-differentiated macrophage cytokine production by activating akt/mammalian target of rapamycin complex 1 pathway

Ko, Jung Hwa, Oh, Joo Youn·2023·Cytotherapy

Abstract

Background aims The Akt/mammalian target of rapamycin (mTOR) pathway in macrophages converges inflammatory and metabolic signals from multiple receptors to regulate a cell's survival, metabolism and activation. Although mesenchymal stromal cells (MSCs) are well known to modulate macrophage activation, the effects of MSCs on the Akt/mTOR pathway in macrophages have not been elucidated. Methods We herein investigated whether MSCs affect the Akt/mTOR complex 1 (mTORC1) pathway to regulate macrophage polarization. Results Results showed that human bone marrow-derived MSCs induced activation of Akt and its downstream mTORC1 signaling in THP-1-differentiated macrophages in a p62/sequestosome 1-independent manner. Inhibition of Akt or mTORC1 attenuated the effects of MSCs on the suppression of tumor necrosis factor-α and interleukin-12 production and the promotion of interleukin-10 and tumor growth factor-β1 in macrophages stimulated by lipopolysaccharide/ATP. Conversely, activation of Akt or mTORC1 reproduced and potentiated MSC effects on macrophage cytokine production. MSCs with cyclooxygenase-2 knockdown, however, failed to activate the Akt/mTORC1 signaling in macrophages and were less effective in the modulation of macrophage cytokine production than control MSCs. Conclusions These data demonstrate that MSCs control THP-1-differentiated macrophage activation at least partly through upregulation of the Akt/mTORC1 signaling in a cyclooxygenase-2-dependent manner.

Integrity signals

Registry

Crossref · 10.1016/j.jcyt.2023.03.013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both iMSC lines successfully suppressed inflammatory activation in LPS-treated THP1 monocytes with significantly reduced activation of the NFκB pathway.

    “Both iMSC lines successfully suppressed inflammatory activation in LPS-treated THP1 monocytes with significantly reduced activation of the NFκB pathway, attesting to their immunomodulatory effects (Ko and Oh, 2023).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ko, J. H., & Oh, J. Y.
Affiliations
Seoul National University (KR)
Corresponding author
Oh, Joo Youn
Venue
Cytotherapy
Publisher
Elsevier BV
Published
2023-08
Volume
25
Issue
8
Pages
858-865
ISSN
1465-3249 (ISSN-L)
OpenAlex
W4367396150
Cited by
3
References
3
Citations by year
2026: 2 · 2024: 1
FWCI
0.52
Type
journal article
Language
en
Open access
closed
Locations
  • Cytotherapy (publishedVersion)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
  • National Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning (2021R1A2C3004532)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
mesenchymal stem cells, macrophage polarization, Akt/mTORC1 signaling, THP-1 macrophages, macrophage cytokine production, cyclooxygenase-2, p62/sequestosome 1, TNF-α, IL-12, IL-10, bone marrow-derived MSCs
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Humans, Macrophages, Proto-Oncogene Proteins c-akt, Cyclooxygenase 2, TOR Serine-Threonine Kinases, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review